Effect of CC and CXC Chemokines on HIVYu-2 Replication in the DC-T-Cell Coculture System When Present During Phase I Only or During Phases I + II
| Chemokine . | p24 Production (ng/mL) in the Presence of Chemokines . | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | (A) Chemokines Present During Phase I Only . | (B) Chemokines Present Throughout Phases I + II . | . | . | . | . | . | ||||||
| . | . | (days postinfection) . | (days postinfection) . | . | . | . | . | . | ||||||
| . | . | 3 . | 5 . | 7 . | 10 . | 3 . | 5 . | 7 . | 10 . | . | . | . | . | . |
| RANTES | 0.00 | 0.17 | 1.4 | 8.6 | 0.00 | 0.02 | 0.00 | 0.097 | ||||||
| MIP-1α | 0.2 | 0.5 | 3.35 | 19.6 | 0.02 | 0.23 | 0.569 | 1.92 | ||||||
| MIP-1β | 0.00 | 0.36 | 2.94 | 20.6 | 0.00 | 0.12 | 0.86 | 17.5 | ||||||
| MCP-1 | 0.00 | 0.62 | 4.8 | 69 | 0.00 | 0.3 | 2.89 | 16.9 | ||||||
| IP10 | 0.00 | 0.24 | 2.9 | 106 | 0.00 | 0.55 | 4.69 | 54.8 | ||||||
| IL-8 | 0.00 | 0.785 | 6.5 | 54 | 0.00 | 0.49 | 4.63 | 61 | ||||||
| None | 0.2 | 0.58 | 5.49 | 77 | 0.2 | 0.58 | 5.49 | 77 | ||||||
| Chemokine . | p24 Production (ng/mL) in the Presence of Chemokines . | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | (A) Chemokines Present During Phase I Only . | (B) Chemokines Present Throughout Phases I + II . | . | . | . | . | . | ||||||
| . | . | (days postinfection) . | (days postinfection) . | . | . | . | . | . | ||||||
| . | . | 3 . | 5 . | 7 . | 10 . | 3 . | 5 . | 7 . | 10 . | . | . | . | . | . |
| RANTES | 0.00 | 0.17 | 1.4 | 8.6 | 0.00 | 0.02 | 0.00 | 0.097 | ||||||
| MIP-1α | 0.2 | 0.5 | 3.35 | 19.6 | 0.02 | 0.23 | 0.569 | 1.92 | ||||||
| MIP-1β | 0.00 | 0.36 | 2.94 | 20.6 | 0.00 | 0.12 | 0.86 | 17.5 | ||||||
| MCP-1 | 0.00 | 0.62 | 4.8 | 69 | 0.00 | 0.3 | 2.89 | 16.9 | ||||||
| IP10 | 0.00 | 0.24 | 2.9 | 106 | 0.00 | 0.55 | 4.69 | 54.8 | ||||||
| IL-8 | 0.00 | 0.785 | 6.5 | 54 | 0.00 | 0.49 | 4.63 | 61 | ||||||
| None | 0.2 | 0.58 | 5.49 | 77 | 0.2 | 0.58 | 5.49 | 77 | ||||||
DC were pretreated with 500 ng of the respective chemokine for 60 minutes and exposed to Yu-2 (6 ng/mL) for 60 minutes at 37°C. Chemokine-treated, virus-pulsed DC were washed four times with phosphate-buffered saline and treated with trypsin for 10 minutes. The cells were then washed twice and cocultivated with PHA-stimulated, uninfected autologous T cells. (A) chemokines were added only one time during phase I to pretreat DC; (B) the cultures were maintained in the continuous presence of the respective chemokine, phases I + II. Both sets of experiments were performed simultaneously on DC obtained from the same single donor. Therefore, one untreated control was used for both phase I and phase II chemokine treatment.